Overcoming Persistent Hurdles in Oncology
At Sapience, we think boldly about the possibilities for treating cancer, providing new options for patients that address the disease where it forms. We are developing first-in-class peptide antagonists against the most elusive oncogenic and immune-modulating drug targets.
Advancing Intelligently-Designed Therapeutics
We are pioneering a new class of peptide antagonists called SPEARs™ (Stabilized Peptides Engineered Against Regulation). SPEARs hold the potential to combine the best properties of small molecules and antibodies in disrupting oncogenic and immune regulation – allowing us to address cancer at the source of disease. Two of our SPEARs, ST101 and ST316, are recruiting clinical studies in patients with advanced solid tumors.
Recent News
Sapience Therapeutics Presents New ST101 Phase 2 Clinical Data in GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
Sapience Therapeutics Announces Poster Presentation with New Clinical Data for ST101 in GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
Sapience Therapeutics Presents ST101 Clinical Data and ST316 Preclinical Data at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sapience Therapeutics Announces Presentation of ST101 Clinical Data at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sapience Therapeutics Announces First Patient Dosed in Phase 1-2 Clinical Study of its First-in-Class β-catenin Antagonist, ST316, in Advanced Solid Tumors
Sapience Therapeutics Awarded $2 Million Grant to Evaluate the Therapeutic Potential of ST316, a First-in-Class β-catenin Antagonist
Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023
Sapience Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
Sapience Therapeutics Announces Late-Breaking Research Poster Presentations on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023
Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors
Sapience Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day
Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer
Sapience Therapeutics to Participate in Upcoming Investor Conferences
Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy from Phase 2 Study in Recurrent Glioblastoma (GBM) at Society for Neuro-Oncology (SNO) Annual Meeting
Sapience Therapeutics Presents Data on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy, Long-Term Exposure and Safety in Phase 1-2 at 34th EORTC-NCI-AACR Symposium
Sapience Therapeutics Announces Poster Presentation on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Sapience Therapeutics Awarded SBIR Phase 2 Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST101 in Breast Cancer
Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics
Sapience Therapeutics Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101 in Recurrent and Newly Diagnosed GBM Patients
Sapience Therapeutics to Participate Virtually in Upcoming August Investor Conferences
Sapience Therapeutics Presents Phase 1 Data at ASCO 2022 Including Efficacy Proof-of-Concept with ST101 in Patients with Refractory Solid Tumors
Sapience Therapeutics Announces Expansion of Phase 2 Study Arm with ST101 in Patients with Recurrent Glioblastoma (GBM) Based on Confirmed Partial Response (PR)
Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions
Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022
Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma
Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways
Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs
Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect
Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022
Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel
Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference
Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma
Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium
Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference
Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research
Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program
Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021
Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021
Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101
Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect
Sapience Therapeutics to Present at BIO Digital 2021
Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models
Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases
Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021
Sapience Therapeutics to Present at the Upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley
Sapience Therapeutics Appoints J. Andrew Sanford to Its Board of Directors
Sapience Therapeutics Renews Drug Discovery Pact with the University of Bath
Sapience Therapeutics Completes $14 million Preferred Stock Financing
Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute
Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors
Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II
Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications
Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications
Sapience Therapeutics to Present at Biotech Showcase 2020
Sapience Therapeutics to Present at the 2019 Life Sciences Summit
Sapience Therapeutics to Present at the 2019 BIO Investor Forum
Sapience Therapeutics Builds Clinical Team with Appointment of Alice Bexon, MD, as Chief Medical Officer
Sapience Therapeutics to Present at the 2019 BIO International Convention
Sapience Therapeutics to Present Poster on ST101 at the 2019 American Association for Cancer Research Annual Meeting
Sapience Therapeutics to Present at 2019 BIO CEO & Investor Conference
Sapience Therapeutics to Present at Biotech Showcase 2019
Sapience Therapeutics, Inc. Selected as a Winner of the JLABS NYC QuickFire Challenge
Sapience Therapeutics Enters into Drug Discovery Pact with the University of Bath
Sapience Therapeutics Adds Biotech Veteran, Christian S. Schade, to Board of Directors
Sapience Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ST-36 for the Treatment of Glioma
Sapience Therapeutics Adds Former Head of the National Cancer Institute, Samuel Broder, MD, to Board of Directors
Sapience Therapeutics, Inc. Enters Into Exclusive License Agreement With Columbia University for Novel Cancer Treatment
Sapience Therapeutics Completes $22.5 Million Series A Financing